Octreotide acetate

醋酸奥曲肽

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameOctreotide acetate
Drug Alias NameOctreotidum acetate奥瑞肽醋酸盐醋酸奥瑞肽Octreotida acetateOcteotride SDI +[16] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionGrowth hormone releasing factor antagonistsSomatostatin receptor agonists
TargetsSomatostatin receptorGrowth hormone releasing factor
Therapy Area/IndicationsDiabetic macular oedemaPancreatic neuroendocrine tumors (pNET)Gastroenteropancreatic neuroendocrine tumor +[46] 
Global Approved IndicationsHypoglycemiaCongenital HyperinsulinismAcromegaly +[9] 
Approved Indications in ChinaAcromegalyMalignant Carcinoid SyndromeNeuroendocrine Tumors
Original Approved Country/TerritoryJapan
Original Approved Date1989/07/10
Country/TerritoryBelgiumBulgariaCanada +[30] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesNovartis Pharma Schweiz AgUniversity College LondonNovartis Pharma Ag +[6] 
Inactive CompaniesRadboud University Medical CenterAzidus BrasilAmryt Pharmaceuticals Dac +[15] 
Active IndicationsDiabetic macular oedemaPancreatic neuroendocrine tumors (pNET)Gastroenteropancreatic neuroendocrine tumor +[15] 
Inactive IndicationsVomitingNauseaHyperphagia +[31] 

Other Information

ATC CodeH01CB02
Related LinksWikipediaDrugBankKEGG